SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO® (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positiv ...

ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction. "Under this expanded agreement, Optime Care will now manage commercia ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio. It has been roughly seven months since my last Rigel Pharmaceuticals (NASDAQ: RIGL ) article , where I discussed their strategic acquisition of GAVRETO (pralsetinib), which, I thought, had a competitive edge over Eli Lilly's ( LLY ) Retevmo. Since then ...

文章核心观点 - Rigel Pharmaceuticals (RIGL)近几个月股价上涨近50.1%,主要得益于公司成功执行、创新产品组合、战略合作伙伴关系以及持续的研发管线进展 [1] - 公司的主要价值驱动因素是FDA批准的药物Tavalisse、Rezlidhia和Gavreto [1] 公司概况 - Rigel Pharmaceuticals是一家专注于创新药物研发的生物制药公司 [1] - 公司拥有10年投资银行从业经验的资深研究分析师,专门负责行业和公司研究 [1] - 分析师擅长解读各种新闻、事件、财报等,发现潜在的投资机会和风险 [1] 公司产品 - Tavalisse是公司获批的首个自主研发的药物,用于治疗成人原发免疫性血小板减少症 [1] - Rezlidhia是公司获批的第二个自主研发的药物,用于治疗成人急性髓系白血病 [1] - Gavreto是公司与Blueprint Medicines合作开发的靶向RET基因突变的非小细胞肺癌药物 [1] 公司研发管线 - 公司持续推进研发管线,包括针对自身免疫性疾病、血液肿瘤和实体瘤的多个候选药物 [1] - 公司与多家制药公司建立了战略合作关系,共同推进研发项目 [1]

Rigel Pharmaceuticals (RIGL) shares ended the last trading session 19.7% higher at $16.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.6% gain over the past four weeks. Earlier this month, the company enrolled the first patient in a phase Ib/II triplet therapy study, which evaluated its marketed drug Rezlidhia (olutasidenib) in combination with decitabine and venetoclax for the treatment of mutated isocitrate ...

First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine ...

Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA SOUTH SAN FRANCISCO, Calif ...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference, Boston, MA Mr. Schorno will participate in one-on-one meetings on Thursday, September 5th. H.C. Wainwright 26th Annual Global Investment Con ...

财务数据和关键指标变化 - 公司第二季度净产品销售额为3350万美元,同比增长40% [10][15] - TAVALISSE第二季度净销售额为2640万美元,同比增长25% [18][63] - REZLIDHIA第二季度净销售额为520万美元,同比增长102% [23][63] - GAVRETO第二季度净销售额为190万美元 [63] - 公司第二季度总成本和费用为3640万美元,同比增加13% [67] 各条业务线数据和关键指标变化 - TAVALISSE销量增长主要来自新患者的持续增加和复购 [90][91] - REZLIDHIA在社区医疗机构的销量占比约为四分之一,显示了这一细分市场的重要性 [24][25] - GAVRETO在6月底成功转移至Rigel销售,公司提前完成了从Genentech/Blueprint的过渡 [27][31][35] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司计划继续通过授权引进或收购新产品来扩大产品组合,关注与公司现有能力相匹配的后期阶段产品 [97][98] - 公司正在与MD Anderson和CONNECT合作,拓展olutasidenib在AML、MDS和胶质瘤等适应症的开发 [43][44][48] - 公司的R289在低危MDS中的1b期试验正在进展,预计年内公布初步数据 [55][56] 管理层对经营环境和未来前景的评论 - 公司有信心在未来几年实现收入指引,并有望在今年实现接近净收支平衡 [84][85] - 公司有信心通过执行力和产品组合的持续扩张来实现业务的持续增长 [70][71] 其他重要信息 - 无相关内容 问答环节重要的提问和回答 问题1 **Yigal Nochomovitz 提问** 关于R289 1b期试验新增剂量组的原因 [76][77] **Lisa Rojkjaer 回答** 公司希望彻底探索一次性和两次剂量的安全性、药代动力学和初步疗效,以确定最佳剂量进入2期扩展 [78] 问题2 **Yigal Nochomovitz 提问** 关于与MD Anderson合作的AML试验,与之前的ivosidenib联合方案相比的目标 [79][80] **Lisa Rojkjaer 回答** olutasidenib与ivosidenib有不同的结构和结合特性,公司希望评估olutasidenib在这一设置下的疗效,特别是联合口服去甲基化药物的潜力 [81][82] 问题3 **Kristen Kluska 提问** 公司是否考虑提供未来几年的收入指引 [83][84][85] **Raul Rodriguez 回答** 公司目前已接近净收支平衡,未来有望产生现金流,可用于支持临床试验等,公司会考虑在不太遥远的将来提供收入指引

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 83.78%. A quarter ago, it was expected that this drug developer would post a loss of $0.30 per share when it actually produced a loss of $0.50, delivering a surprise of -66.67%. Over the last four quarters, the comp ...